Quarterly report pursuant to Section 13 or 15(d)

Note 13 - Segment Information - Financial Information Relating to Reportable Segments (Details)

v3.21.1
Note 13 - Segment Information - Financial Information Relating to Reportable Segments (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Mar. 31, 2021
Mar. 31, 2020
Revenues, net $ 243,552 $ 194,680 $ 672,004 $ 562,857
Operating income 68,626 47,791 168,714 118,109
Costs recognized on sale of acquired inventory     (91) 0
Corporate general, selling, and administrative expenses (82,596) (66,318) (238,310) (203,358)
Operating Segments [Member]        
Operating income 98,809 72,108 266,188 194,393
Costs recognized on sale of acquired inventory (68) 0 (91) 0
Amortization of acquisition related intangible assets (15,222) (15,459) (45,750) (45,467)
Acquisition related expenses (1,731) 322 (6,289) (107)
Stock based compensation, inclusive of employer taxes (11,968) (8,088) (41,525) (27,505)
Restructure costs 0 0 (142) 0
Operating Segments [Member] | Protein Sciences [Member]        
Revenues, net 185,623 145,509 512,248 428,021
Operating income 88,392 65,046 238,991 185,456
Operating Segments [Member] | Diagnostics and Genomics [Member]        
Revenues, net 58,093 49,411 160,687 135,808
Operating income 10,417 7,062 27,197 8,937
Intersegment Eliminations [Member]        
Revenues, net (164) (240) (931) (972)
Corporate, Non-Segment [Member]        
Corporate general, selling, and administrative expenses $ (1,194) $ (1,092) $ (3,677) $ (3,205)